AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
daprodustat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors | 5421 | 960539-70-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Daprodustat is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 39 | |||
| kinase-selectivity-class | AXL,GRK2,TTK | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 29, 2020 | PMDA | GlaxoSmithKline | |
| Feb. 1, 2023 | FDA | GLAXOSMITHKLINE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haemoglobin increased | 51.22 | 41.47 | 11 | 462 | 7470 | 90620504 |
| Renal impairment | 49.21 | 41.47 | 19 | 454 | 105402 | 90522572 |
| Cerebral infarction | 46.33 | 41.47 | 13 | 460 | 26583 | 90601391 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haemoglobin increased | 75.35 | 39.26 | 17 | 894 | 9130 | 110579258 |
| Cerebral infarction | 65.41 | 39.26 | 22 | 889 | 51816 | 110536572 |
| Renal impairment | 57.87 | 39.26 | 29 | 882 | 188416 | 110399972 |
| Cardiac failure | 55.04 | 39.26 | 28 | 883 | 187598 | 110400790 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B03XA07 | BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS OTHER ANTIANEMIC PREPARATIONS Other antianemic preparations |
| FDA MoA | N0000194079 | Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors |
| FDA EPC | N0000194080 | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:73336 | vulnerary |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:102248 | EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor |
Related Drugs by ATC class:
B03XA Other antianemic preparations 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia of renal disease | indication | 234348004 | |
| Anemia in chronic kidney disease | indication | 707323002 | |
| Uncontrolled hypertension | contraindication | 38341003 | DOID:10763 |
| Concomitant administration of strong CYP2C8 inhibitors | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 1MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11643397 | June 22, 2027 | A METHOD OF TREATING ANEMIA |
| 1MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8557834 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 1MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8815884 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 2MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11643397 | June 22, 2027 | A METHOD OF TREATING ANEMIA |
| 2MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8557834 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 2MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8815884 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 4MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11643397 | June 22, 2027 | A METHOD OF TREATING ANEMIA |
| 4MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8557834 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 4MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8815884 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 6MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11643397 | June 22, 2027 | A METHOD OF TREATING ANEMIA |
| 6MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8557834 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 6MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8815884 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 8MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11643397 | June 22, 2027 | A METHOD OF TREATING ANEMIA |
| 8MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8557834 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 8MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 8815884 | June 22, 2027 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| 1MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11117871 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 1MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11649217 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 2MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11117871 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 2MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11649217 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 4MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11117871 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 4MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11649217 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 6MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11117871 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 6MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11649217 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 8MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11117871 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
| 8MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | 11649217 | March 13, 2038 | A METHOD OF TREATING ANEMIA |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | Feb. 1, 2028 | NEW CHEMICAL ENTITY |
| 2MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | Feb. 1, 2028 | NEW CHEMICAL ENTITY |
| 4MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | Feb. 1, 2028 | NEW CHEMICAL ENTITY |
| 6MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | Feb. 1, 2028 | NEW CHEMICAL ENTITY |
| 8MG | JESDUVROQ | GLAXOSMITHKLINE | N216951 | Feb. 1, 2023 | DISCN | TABLET | ORAL | Feb. 1, 2028 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Egl nine homolog 1 | Enzyme | INHIBITOR | IC50 | 8.46 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Egl nine homolog 2 | Enzyme | INHIBITOR | IC50 | 8.14 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Egl nine homolog 3 | Enzyme | INHIBITOR | IC50 | 8.26 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Aspartyl/asparaginyl beta-hydroxylase | Enzyme | IC50 | 4.96 | CHEMBL | |||||
| Gamma-butyrobetaine dioxygenase | Enzyme | IC50 | 4.89 | CHEMBL | |||||
| Hypoxia-inducible factor 1-alpha inhibitor | Enzyme | IC50 | 4.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D10874 | KEGG_DRUG |
| JVR38ZM64B | UNII |
| C4519188 | UMLSCUI |
| CHEBI:229223 | CHEBI |
| CHEMBL3544988 | ChEMBL_ID |
| 91617630 | PUBCHEM_CID |
| DB11682 | DRUGBANK_ID |
| 10167 | INN_ID |
| C000599718 | MESH_SUPPLEMENTAL_RECORD_UI |
| 8455 | IUPHAR_LIGAND_ID |
| 4042585 | VANDF |
| A0W | PDB_CHEM_ID |
| 364979 | MMSL |
| 41216 | MMSL |
| d09985 | MMSL |
| 019290 | NDDF |
| 2628210 | RXNORM |
| JVR38ZM64B | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Jesduvroq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0897 | TABLET, FILM COATED | 1 mg | ORAL | NDA | 30 sections |
| Jesduvroq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0903 | TABLET, FILM COATED | 2 mg | ORAL | NDA | 30 sections |
| Jesduvroq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0906 | TABLET, FILM COATED | 4 mg | ORAL | NDA | 30 sections |
| Jesduvroq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0911 | TABLET, FILM COATED | 6 mg | ORAL | NDA | 30 sections |
| Jesduvroq | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0173-0914 | TABLET, FILM COATED | 8 mg | ORAL | NDA | 30 sections |